Trevi Therapeutics (TRVI) Other Non-Current Assets (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Other Non-Current Assets of $2.6 million for Q1 2026, up 982.99% year-over-year from $241000.0 in Q1 2025, and up 181.25% quarter-over-quarter from $928000.0 in Q4 2025.
Trevi Therapeutics (TRVI) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Other Non-Current Assets history runs 9 years deep, the most recent figure standing at $2.6 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 982.99% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (up 982.99% YoY), while the FY2025 annual figure was $928000.0, up 281.89% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $2.6 million, up from $928000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $2.6 million in Q1 2026, with the low at $68000.0 in Q2 2023.
- The 5-year median for Other Non-Current Assets is $273000.0 (2024), against an average of $462235.3.
- The sharpest annual moves came in 2023 and 2026: Other Non-Current Assets sank 83.54% in 2023, then surged 982.99% in 2026.
- Trevi Therapeutics' Other Non-Current Assets stood at $205000.0 in 2022, then jumped by 44.88% to $297000.0 in 2023, then dropped by 18.18% to $243000.0 in 2024, then surged by 281.89% to $928000.0 in 2025, then surged by 181.25% to $2.6 million in 2026.
- Business Quant data shows TRVI's Other Non-Current Assets at $2.6 million in Q1 2026, $928000.0 in Q4 2025, and $103000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 3.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.94 Mn |
| Mar 31, 2026 | 2.61 Mn |
| Dec 31, 2025 | 928,000.00 |
| Sep 30, 2025 | 103,000.00 |
| Jun 30, 2025 | 68,000.00 |
| Mar 31, 2025 | 241,000.00 |
| Dec 31, 2024 | 243,000.00 |
| Sep 30, 2024 | 256,000.00 |
| Jun 30, 2024 | 273,000.00 |
| Mar 31, 2024 | 311,000.00 |
| Dec 31, 2023 | 297,000.00 |
| Sep 30, 2023 | 297,000.00 |
| Jun 30, 2023 | 68,000.00 |
| Mar 31, 2023 | 225,000.00 |
| Dec 31, 2022 | 205,000.00 |
| Sep 30, 2022 | 922,000.00 |
| Jun 30, 2022 | 413,000.00 |
| Mar 31, 2022 | 398,000.00 |
| Dec 31, 2021 | 334,000.00 |
| Dec 31, 2020 | 532,000.00 |